Interstitial Lung Disease Trial, Recruiting (NCT07004595)

Interstitial Lung Disease Trial, Recruiting NCT07004595 Sponsor: Nantes University Hospital Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07004595 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People diagnosed with a scarring lung condition known as fibrosing interstitial lung disease (ILD), based on specific international medical guidelines from 2022.
People aged 65 years or older.
People attending outpatient appointments, such as a scheduled clinic visit, day hospital, or a short planned hospital stay.
People who speak French.
People who have been given an information sheet about the study and have not raised any objection to taking part.

Who may not be able to join:

People who are under legal guardianship, curatorship, or another form of court-ordered legal protection.
People with cognitive difficulties that would make it hard to complete questionnaires.
People whose CT scan (a detailed internal imaging scan) shows an early-stage pattern of a specific lung scarring type called "usual interstitial pneumonia (UIP)," as defined by the 2022 international guidelines (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07004595

Sponsor: Nantes University Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

More information: https://clinicaltrials.gov/study/NCT07004595

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People diagnosed with a scarring lung condition known as fibrosing interstitial lung disease (ILD), based on specific international medical guidelines from 2022.
People aged 65 years or older.
People attending outpatient appointments, such as a scheduled clinic visit, day hospital, or a short planned hospital stay.
People who speak French.
People who have been given an information sheet about the study and have not raised any objection to taking part.

Who may not be able to join:

People who are under legal guardianship, curatorship, or another form of court-ordered legal protection.
People with cognitive difficulties that would make it hard to complete questionnaires.
People whose CT scan (a detailed internal imaging scan) shows an early-stage pattern of a specific lung scarring type called "usual interstitial pneumonia (UIP)," as defined by the 2022 international guidelines (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Nantes University Hospital

Registry

ClinicalTrials.gov

Start date

20 July 2025

Est. completion

20 February 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

to analyze the prognostic value of the phenotypes "frail and sarcopenic," "frail only," "sarcopenic only," and "robust" on the outcomes of patients with fibrosing ILDs; to analyze the progression of sarcopenia

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov